Adrian M. Di Bisceglie – 17 January 2019

Gyongyi Szabo, Patrick S. Kamath, Vijay H. Shah, Mark Thursz, Philippe Mathurin – 15 January 2019 – A joint meeting of the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) was held in London on September 30 and October 1, 2017. The goals of the meeting were to identify areas of broad agreement and disagreement, develop consensus, and determine future directions to ultimately reduce the burden, morbidity, and mortality of alcohol‐related liver disease (previously termed alcoholic liver disease).

Gyongyi Szabo, Patrick S. Kamath, Vijay H. Shah, Mark Thursz, Philippe Mathurin – 15 January 2019 – A joint meeting of the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) was held in London on September 30 and October 1, 2017. The goals of the meeting were to identify areas of broad agreement and disagreement, develop consensus, and determine future directions to ultimately reduce the burden, morbidity, and mortality of alcohol‐related liver disease (previously termed alcoholic liver disease).

Mauro Panteghini, Ferruccio Ceriotti – 14 January 2019

Hui Chen, Feng Gao, Mian He, Xiao Fan Ding, Aikha M. Wong, Siu Ching Sze, Allen C. Yu, Tingting Sun, Anthony W‐H. Chan, Xin Wang, Nathalie Wong – 13 January 2019 – Alternative splicing (AS) allows generation of cell type–specific mRNA transcripts and contributes to hallmarks of cancer. Genome‐wide analysis for AS in human hepatocellular carcinoma (HCC), however, is limited. We sought to obtain a comprehensive AS landscape in HCC and define tumor‐associated variants.

Jan Hinrich Bräsen, Young‐Seon Mederacke, Jessica Schmitz, Kateryna Diahovets, Abedalrazag Khalifa, Björn Hartleben, Fermín Person, Thorsten Wiech, Eric Steenbergen, Anika Großhennig, Michael P. Manns, Roland Schmitt, Ingmar Mederacke – 11 January 2019 – Impairment of renal function often occurs in patients with liver disease. Hepatorenal syndrome is a significant cause of acute kidney injury (AKI) in patients with cirrhosis (HRS‐AKI, type 1). Causes of non‐HRS‐AKI include cholemic nephropathy (CN), a disease that is characterized by intratubular bile casts and tubular injury.

Catelyn Coyle, Anne C. Moorman, Tyler Bartholomew, Gary Klein, Helena Kwakwa, Shruti H. Mehta, Deborah Holtzman – 11 January 2019 – Improving care and treatment for persons infected with hepatitis C virus (HCV) can reduce HCV‐related morbidity and mortality. Our primary objective was to examine the HCV care continuum among patients receiving care at five federally qualified health centers (FQHCs) in Philadelphia, PA, where a testing and linkage to care program had been established.

Jan Hinrich Bräsen, Young‐Seon Mederacke, Jessica Schmitz, Kateryna Diahovets, Abedalrazag Khalifa, Björn Hartleben, Fermín Person, Thorsten Wiech, Eric Steenbergen, Anika Großhennig, Michael P. Manns, Roland Schmitt, Ingmar Mederacke – 11 January 2019 – Impairment of renal function often occurs in patients with liver disease. Hepatorenal syndrome is a significant cause of acute kidney injury (AKI) in patients with cirrhosis (HRS‐AKI, type 1). Causes of non‐HRS‐AKI include cholemic nephropathy (CN), a disease that is characterized by intratubular bile casts and tubular injury.

Naveed Z. Janjua, Maryam Darvishian, Stanley Wong, Amanda Yu, Carmine Rossi, Alnoor Ramji, Eric M. Yoshida, Zahid A. Butt, Hasina Samji, Mei Chong, Nuria Chapinal, Darrel Cook, Maria Alvarez, Mark Tyndall, Mel Krajden, the British Columbia Hepatitis Testers Cohort Team – 10 January 2019 – We evaluated the effectiveness of ledipasvir/sofosbuvir (LDV/SOF) in treating hepatitis C virus (HCV) genotype 1 and SOF/velpatasvir (SOF/VEL) for all genotypes among people who inject drugs (PWID) and those not injecting drugs and who were on or off opioid agonist therapy (OAT).

Maria Hukkinen, Jouko Lohi, Päivi Heikkilä, Reetta Kivisaari, Timo Jahnukainen, Hannu Jalanko, Mikko P. Pakarinen – 9 January 2019 – We investigated noninvasive follow‐up markers for histologic liver fibrosis and portal hypertension (PH) in patients with biliary atresia after successful portoenterostomy (PE). Among children with bilirubin <20 µmol/L after PE (n = 39), Metavir fibrosis stage was evaluated at PE and in follow‐up protocol liver biopsies (n = 83). PH was defined as endoscopically confirmed esophageal varices or thrombocytopenia associated with splenomegaly.